PDF(Pubmed)
Abstract：
Almost 75% of renal cancers are renal clear cell carcinomas (KIRC). Accumulative evidence indicates that epigenetic dysregulations are closely related to the development of KIRC. Cancer immunotherapy is an effective treatment for cancers. The aim of this study was to identify immune-related differentially expressed genes (IR-DEGs) associated with aberrant methylations and construct a risk assessment model using these IR-DEGs to predict the prognosis of KIRC. Two IR-DEGs (SLC11A1 and TNFSF14) were identified by differential expression, correlation analysis, and Cox regression analysis, and risk assessment models were established. The area under the receiver operating characteristic (ROC) curve (AUC) was 0.6907. In addition, we found that risk scores were significantly associated with 31 immune cells and factors. Our present study not only shows that two IR-DEGs can be used as prognosis signatures for KIRC, but also provides a strategy for the screening of suitable prognosis signatures associated with aberrant methylation in other cancers.
摘要：
几乎75%的肾癌是肾透明细胞癌(KIRC)。越来越多的证据表明，表观遗传失调与KIRC的发展密切相关。癌症免疫疗法是癌症的有效治疗方法。这项研究的目的是鉴定与异常甲基化相关的免疫相关差异表达基因（IR-DEGs），并使用这些IR-DEGs构建风险评估模型来预测KIRC的预后。通过差异表达鉴定出两个IR-DEGs(SLC11A1和TNFSF14),相关分析，和Cox回归分析，建立了风险评估模型。受试者工作特征(ROC)曲线下面积(AUC)为0.6907。此外,我们发现风险评分与31种免疫细胞和因子显著相关.我们目前的研究不仅表明两个IR-DEGs可以用作KIRC的预后标志，但也提供了一种用于筛选与其他癌症中异常甲基化相关的合适预后特征的策略。
